Our data on VEGFR2 expression linked to HIF2α rather than HIF1α expression suggest that the angiogenic phenotype of ccRCC may define the favorable prognosis subgroup, which can be more sensitive to antiangiogenic agents while the HIF1α-high/HIF2α-low subgroup may define the adverse prognosis subgroup of ccRCC, where VEGFR2 expression is also low. Here, EPAS1 is linked to nonpapillary renal cell carcinoma.